YD Bio (YDES) Receivables - Other (2024 - 2025)
YD Bio (YDES) posted quarterly Receivables - Other of $291.5 billion for Q4 2025, up 1622.34% year-over-year from $16.9 billion in Q4 2024, and up 1622.34% quarter-over-quarter from $16.9 billion in Q4 2024.
YD Bio (YDES) Receivables - Other (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Receivables - Other for 2 consecutive years, with $291.5 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Other rose 1622.34% year-over-year to $291.5 billion; the TTM figure through Dec 2025 stood at $291.5 billion (up 1622.34% YoY), while the FY2025 annual figure was $291.5 billion, up 1622.34% from the prior year.
- Receivables - Other climbed to $291.5 billion in Q4 2025 per YDES's latest filing, from $16.9 billion in the prior quarter.
- Across five years, Receivables - Other topped out at $291.5 billion in Q4 2025 and bottomed at $16.9 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | YD Bio | 322.06 Mn | 316.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 291.54 Bn |
| Dec 31, 2025 | 291.54 Bn |
| Dec 31, 2024 | 16.93 Bn |
| Dec 31, 2024 | 16.93 Bn |